[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367925-105":59,"doc-detail-367925-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nsd3nutm1-fusion-evidenced-on-rna-sequencing-in-poorly-differentiated-thyroid-cancer-a-report-of-two-cases","NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer - a report of two cases","","Nuclear protein in testis (NUT) carcinomas are aggressive, poorly or undifferentiated cancers defined by NUTM1 fusions; such fusions are rarely seen in primary thyroid cancer and are reported mainly in patients aged ≤45 years. Two patients older than 65 years presented with locally advanced poorly differentiated thyroid cancer and extensive FDG-avid metastases. RNA sequencing using an institutional next-generation panel identified the NSD3::NUTM1 translocation in both cases. The report supports adding NUTM1-fusion searching to RNA sequencing panels for advanced refractory thyroid cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nsd3nutm1-fusion-evidenced-on-rna-sequencing-in-poorly-differentiated-thyroid-cancer-a-report-of-two-cases/367925/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nsd3nutm1-fusion-evidenced-on-rna-sequencing-in-poorly-differentiated-thyroid-cancer-a-report-of-two-cases/367925.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What defines NUT carcinomas and what role does NUTM1 play in this disease?","Question",{"text":112,"@type":113},"NUT carcinomas are aggressive cancers defined by NUTM1 fusions. These fusions can be detected using immunohistochemistry, fluorescence in situ hybridization, or RNA sequencing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the NSD3::NUTM1 translocation detected in the two reported thyroid cancer cases?",{"text":117,"@type":113},"In both patients, RNA sequencing using the institution’s next-generation sequencing panel provided evidence of the NSD3::NUTM1 translocation.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do the authors recommend searching for NUTM1 fusions in RNA sequencing panels?",{"text":121,"@type":113},"Because NUTM1 fusions are very infrequent and not routinely sought in poorly differentiated or anaplastic thyroid cancer, adding this search may better identify advanced refractory cases where diagnosis and management are challenging.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367925,1790316371,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","European Thyroid Journal (2025) 14 e250100  \n[https://doi.org/10.1530/ETJ-25-0100](https://doi.org/10.1530/ETJ-25-0100)  \nCASE REPORT  \nReceived 28 March 2025  \nAccepted 23 September 2025 Available online 24 September 2025 Version of Record published 6 October 2025  \n\n| NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases\u003Cbr>Renaud Ciappuccini􀀁1,2, Virginie Saguet-Rysanek3, Paul-Antoine Bompain1, Jacques Balosso4, Raphal Leman5, Laurent Castera5 and Stphane Bardet1\u003Cbr>1Department of Nuclear Medicine and Thyroid Unit, François Baclesse Comprehensive Cancer Center, Caen, France\u003Cbr>2Normandie University, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), Caen, France\u003Cbr>3Department of Pathology, François Baclesse Comprehensive Cancer Center, Caen, France\u003Cbr>4Department of Radiotherapy, François Baclesse Comprehensive Cancer Center, Caen, France\u003Cbr>5Laboratory of Cancer Biology and Genetics, François Baclesse Comprehensive Cancer Center, Caen, France\u003Cbr>Correspondence should be addressed to R Ciappuccini: [r.ciappuccini@baclesse.unicancer.fr](r.ciappuccini@baclesse.unicancer.fr) |\n| --- |\n| Abstract\u003Cbr>Background: Nuclear protein in testis (NUT) carcinomas are aggressive, poorly or undifferentiated cancers, generally arising from midline structures. This subtype of squamous cell carcinoma is rare and has a poor prognosis. NUT cancers are deﬁned by NUTM1 fusions. Rearrangements of the NUTM1 gene have rarely been described in primary thyroid cancer and are mainly reported in patients ≤45 years old. NSD3::NUTM1 translocation is the most common NUTM1 fusion transcript reported in thyroid cancer. As they are very infrequent, NUTM1 fusions are not routinely sought in poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC) .\u003Cbr>Case presentation: We report two PDTC patients >65 years old with locally advanced disease and 18 FDG-avid distant metastases. NSD3::NUTM1 translocation was evidenced in both patients by RNA sequencing using the next-generation sequencing panel of our institution.\u003Cbr>Conclusion: We suggest includingthe search for NUTM1 fusions in the RNA sequencing panel for advanced and refractory thyroid cancers.\u003Cbr>Keywords: NUT carcinoma; NSD3::NUTM1; NUTM1 fusion; thyroid cancer; RNA sequencing; case report |\n\nEstablished facts  \n• Nuclear protein in testis (NUT) carcinomas are rare, aggressive, poorly or undifferentiated cancers with a poor prognosis, generally arising from midline structures in young patients. NUT cancers are deﬁned by NUTM1 fusions that can be evidenced by immunohistochemistry (IHC), ﬂuorescence in situ hybridization, or RNA sequencing.  \n• NUTM1 fusions have rarely been described in primary thyroid cancer, usually in patients ≤45 years old. NSD3:: NUTM1 translocation is the most common NUTM1 fusion transcript reported in thyroid cancer.  \n• As they are very infrequent, NUTM1 fusions are not routinely sought in PDTC or ATC.  \nPublished by Bioscientiﬁca Ltd.  \n[https://etj.bioscienti](https://etj.bioscienti)ﬁ[ca.com](ca.com)  \n© 2025 the author(s)  \nThis work is licensed under a Creative Commons Attribution-NonCommercial 4 .0 International License.  \nR Ciappuccini et al. European Thyroid Journal (2025) 14 e250100  \n[https://doi.org/10.1530/ETJ-25-0100](https://doi.org/10.1530/ETJ-25-0100)  \nNovel insights  \n• We report two patients >65 years old with locally invasive refractory PDTC and NSD3::NUTM1 translocation.  \n• NSD3::NUTM1 translocation might be more systematically sought in locally advanced PDTC/ATC with no point DNA mutations or other rearrangements.  \n• This strategy would better identify these patients, whose pathological diagnosis and clinical management may be challenging.  \nIntroduction  \nNuclear protein in testis (NUT) carcinomas (NC) are aggressive, poorly or undifferentiated cancers, generally arising from midline structures of the thorax or head and neck region (1) . Th","cbCaisyvwIpDDdFd","https://ap.wps.com/l/cbCaisyvwIpDDdFd","pdf",694378,"English","# Abstract\n# Case presentation\n## Conclusion\n# Established facts\n# Novel insights\n# Introduction","[{\"question\":\"What defines NUT carcinomas and what role does NUTM1 play in this disease?\",\"answer\":\"NUT carcinomas are aggressive cancers defined by NUTM1 fusions. These fusions can be detected using immunohistochemistry, fluorescence in situ hybridization, or RNA sequencing.\"},{\"question\":\"How was the NSD3::NUTM1 translocation detected in the two reported thyroid cancer cases?\",\"answer\":\"In both patients, RNA sequencing using the institution’s next-generation sequencing panel provided evidence of the NSD3::NUTM1 translocation.\"},{\"question\":\"Why do the authors recommend searching for NUTM1 fusions in RNA sequencing panels?\",\"answer\":\"Because NUTM1 fusions are very infrequent and not routinely sought in poorly differentiated or anaplastic thyroid cancer, adding this search may better identify advanced refractory cases where diagnosis and management are challenging.\"}]","NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer - a report of two cases | PDF",1790173352,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0fccded049344728da8678d7fc35909.webp",983,1269,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/794795dc9c21d8105b2b16114cc8b055.webp",982,1268,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d67ed344e2aefb995da4d69f738b0399.webp",981,1266,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dd04c7c931c7e62ac2f0f27c0db9770.webp",980,1265]